Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec;23(8):754-766.
doi: 10.1111/bdi.13125. Epub 2021 Sep 15.

Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: A systematic review and meta-analysis

Clare Cullen  1 , Nils Kappelmann  2   3 , Madeha Umer  1 , Ali Abdolizadeh  4 , Muhammad Omair Husain  1   4 , Sarah Bonato  1 , Gaurav Sharma  4 , Siqi Xue  4 , Abigail Ortiz  1   4 , Stefan M Kloiber  1   4 , Benoit H Mulsant  1   4 , Muhammad I Husain  1   4
Affiliations
Meta-Analysis

Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: A systematic review and meta-analysis

Clare Cullen et al. Bipolar Disord. 2021 Dec.

Abstract

Objective: Anxiety symptoms are highly prevalent among individuals with bipolar disorder (BD) but there is little guidance on pharmacotherapy for these symptoms. The objective of this systematic review and meta-analysis was to evaluate the available evidence for pharmacotherapy of comorbid anxiety symptoms in BD.

Methods: Completed randomized clinical trials (RCTs) of medications for BD published prior to December 2020 were identified through a systematic search of MEDLINE, Embase, PsycInfo, Web of Science, clinicaltrials.gov, and the ISRCTN. Data from RCTs measuring anxiety symptoms at baseline and endpoint and all-cause discontinuation were pooled to compare the efficacy and acceptability of medications with control conditions.

Results: Thirty-seven RCTs met our inclusion criteria; 13 placebo-controlled RCTs with 2175 participants had sufficient data to be included in the meta-analysis assessing anxiety symptoms. Compared with placebo, the overall effect size of medications (primarily atypical antipsychotics) on anxiety symptoms was small with a standardized mean difference (SMD) = -0.22 (95% CI: -0.34 to -0.11). Study heterogeneity was low (I2 = 26%). The acceptability of these medications was comparable with placebo with odds ratio of discontinuation from all causes = 0.98 (95% CI: 0.91-1.06).

Conclusion: There is limited evidence for a small anxiolytic effect and good acceptability of pharmacotherapy (primarily atypical antipsychotics) in the treatment of comorbid anxiety symptoms in BD. These results highlight the need for further research on medications other than atypical antipsychotics.

Keywords: anxiety; bipolar disorder; meta-analysis; pharmacotherapy; review.

PubMed Disclaimer

References

REFERENCES

    1. Kauer-Sant'Anna M, Frey BN, Andreazza AC, et al. Anxiety comorbidity and quality of life in bipolar disorder patients. Can J Psychiatry. 2007;52(3):175-181. doi:10.1177/070674370705200309
    1. Spoorthy MS, Chakrabarti S, Grover S. Comorbidity of bipolar and anxiety disorders: AN overview of trends in research. World J Psychiatry. 2019;9(1):7-29. doi:10.5498/wjp.v9.i1.7
    1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64(5):543-552. doi:10.1001/archpsyc.64.5.543
    1. Pavlova B, Perlis RH, Alda M, Uher R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2(8):710-717. doi:10.1016/S2215-0366(15)00112-1
    1. Pavlova B, Perlis RH, Mantere O, et al. Prevalence of current anxiety disorders in people with bipolar disorder during euthymia: a meta-analysis. Psychol Med. 2017;47(6):1107.

Publication types

Substances